Quick answers

What is Retatrutide and what is it used for in research?
Retatrutide is classified within the GLP-1 Metabolic group. Triple-agonist peptide showing dose-dependent weight reduction in Phase 2. Glucagon component drives additional energy expenditure. Research applications focus on the pathways outlined below. All references on this page describe published research only, Retatrutide is supplied for in-vitro and laboratory use, not for human consumption.
How does Retatrutide work?
Primary mechanism: Triple agonist: GLP-1, GIP, and glucagon receptor. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Retatrutide remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Retatrutide research dose?
Published research protocols for Retatrutide describe per-dose ranges of 0.5–12 mg / week, with a weekly total near 0.5–12 mg, administered weekly sc. Typical cycle: research phase. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Retatrutide in Thailand?
Retatrutide is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Retatrutide be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is Retatrutide?

Retatrutide is a research peptide in the GLP-1 Metabolic class. Triple agonist: GLP-1, GIP, and glucagon receptor. It is studied at per-dose ranges of 0.5–12 mg / week (0.5–12 mg weekly), administered weekly sc over cycles of research phase. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Triple-agonist peptide showing dose-dependent weight reduction in Phase 2. Glucagon component drives additional energy expenditure.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Retatrutide work?

Retatrutide is a single-molecule triple agonist at GLP-1, GIP, and glucagon receptors. Glucagon-receptor activity increases hepatic glucose output and energy expenditure, which, when balanced against the glycaemic and satiety effects of GIP/GLP-1 co-agonism, produces dose-dependent weight loss greater than that observed with dual or mono-agonists in published Phase 2 trials.

Receptor binding affinity and post-receptor signalling for Retatrutide remain areas of active investigation; several proposed effects within the GLP-1 Metabolic class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Retatrutide pharmacokinetics

Half-life
Approximately 6 days in Phase 2 data, supporting weekly administration.
Bioavailability
SC bioavailability consistent with other fatty-acid-modified peptide agonists in this class.
Route of administration
Subcutaneous injection once weekly in reported trials.
Metabolic clearance
Proteolytic; long-term safety and clearance pathways still under active investigation.

Retatrutide research timeline

  1. 2023 Jastreboff et al., Phase 2 obesity trial showing dose-dependent weight reduction up to ~24% (N Engl J Med).

Retatrutide dosage & protocol

Reference protocol for Retatrutide (research context only, drawn from published literature):

  • Per dose: 0.5–12 mg / week
  • Weekly total: 0.5–12 mg
  • Frequency: Weekly SC
  • Cycle: Research phase

Retatrutide injection & handling

Reconstitution
Investigational product supplied per trial protocol; no consumer product yet.
Storage
Refrigerated per supplier specification.
Sites used in the research literature
Subcutaneous abdomen or thigh in reported research.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order Retatrutide
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about Retatrutide ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking Retatrutide

Commonly referenced pairing with Retatrutide: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Retatrutide stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Unestablished safety profile. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Compare Retatrutide with: Semaglutide Tirzepatide

Citations

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, phase 2 trial. Lancet. 2023. PMID: 37385280

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.